ArticleTrials2026
The effect of exogenous ketone monoester supplementation on cerebral blood flow and functional brain characteristics in adults with subjective cognitive decline: study protocol for a randomized crossover trial.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06588946 (The Effect of Exogenous Β-OHB Supplementation on Cerebral Blood Flow and Functional Brain Characteristics in Adults with Subjective Cognitive Decline), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Exogenous Β-OHB Supplementation on Cerebral Blood Flow and Functional Brain Characteristics in Adults with Subjective Cognitive Decline
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThere is an urgent need for interventions which reduce dementia risk in aging adults. People with subjective cognitive decline (SCD) have a greater risk of developing dementia compared to age-matched cognitively normal individuals. Impaired cerebral blood flow (CBF) and cerebral glucose hypometabolism are leading mechanisms underlying dementia that could be ideal interventional targets for this population. Recent research, including our own work, has shown that oral consumption of ketone monoesters (KME) can improve CBF and cerebral metabolism, which in turn can improve cognition. The purpose of this study is to investigate the hypothesis that a 14-day KME supplementation intervention in middle-to-older adults with SCD will increase CBF, brain functional connectivity, and cognitive performance in comparison to placebo.
methodsA total of 34 middle-to-older adults (50% female, aged 55-75) with SCD will be recruited for this randomized placebo-controlled crossover double-blind trial. Participants will complete study visits immediately before and after 14 days of thrice-daily supplementation with a KME or a placebo. Following a minimum 14-day washout period, participants will repeat the protocol to complete study visits immediately before and after 14 days of thrice-daily supplementation with the other intervention (KME or placebo). The outcome measures are as follows: (1) CBF, functional brain connectivity, and cerebrovascular function as measured by brain magnetic resonance imaging (MRI) scans, (2) cognitive function assessed via a battery of validated psychometric tests, and (3) blood-borne neurotrophic factors via venous blood sample collection. DISCUSSION: This novel study aims to advance our understanding of how KME could be an effective intervention to combat dementia risk factors and improve aspects of brain health in middle-to-older adults with SCD.
trial registrationClinicalTrials.gov NCT06588946. Registered on 05 September 2024.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.